Solid-Phase vs. Liquid-Phase Peptide Synthesis: How Manufacturing Methods Affect Research Peptide Purity

Solid-phase vs. liquid-phase peptide synthesis is the first fork in the road for any research peptide, and the route chosen decides which impurities a finished lot can contain before a single analytical method is run. Solid-phase synthesis (SPPS) assembles the chain on an insoluble resin and dominates research-scale manufacturing. Liquid-phase synthesis (LPPS) works in solution and survives mainly for short sequences made at large scale. Neither route produces a pure product on its own, which is why the Certificate of Analysis, not the synthesis method, is the document that tells a researcher what is actually in the vial.

For researchers sourcing peptides from Canadian suppliers, the synthesis chemistry is rarely disclosed on a product page, yet it sets the impurity profile the testing laboratory has to look for. This guide explains how each route works, the by-products each one leaves behind, and how those by-products show up on an HPLC chromatogram and a mass spectrum.

Solid-Phase Peptide Synthesis (SPPS): The Research Standard

SPPS was introduced by Robert Bruce Merrifield in 1963 (Merrifield RB, J Am Chem Soc 1963;85:2149-2154) and earned him the 1984 Nobel Prize in Chemistry. The idea is simple. The C-terminal amino acid is attached to an insoluble resin bead, and the chain is extended one protected amino acid at a time. Because the growing peptide is covalently anchored, excess reagents and soluble by-products are removed by filtration and washing after every step, which is what makes the cycle automatable.

Two protecting-group strategies exist. The original Boc chemistry uses the tert-butyloxycarbonyl group on the alpha-amine and requires liquid hydrofluoric acid to release the finished peptide. The Fmoc strategy, based on the 9-fluorenylmethyloxycarbonyl group described by Carpino and Han (J Org Chem 1972;37:3404-3409), removes the temporary protecting group with a mild base such as piperidine and cleaves the finished peptide with trifluoroacetic acid. Fmoc chemistry is now the default for research peptide manufacture, and the review by Behrendt, White and Offer (J Pept Sci 2016;22:4-27) is the standard account of its current state, including microwave heating and the side reactions discussed below.

Why Per-Step Yield Compounds

Each residue added requires a deprotection and a coupling, and neither is quantitative. The arithmetic is unforgiving because the losses multiply. If every coupling proceeded at 99 percent, a 15-residue peptide such as BPC-157, which needs 14 couplings after the first residue is loaded onto the resin, would reach a theoretical crude yield of 0.99 raised to the fourteenth power, about 87 percent, before any purification. At 98 percent per step the same chain falls to roughly 75 percent. At 99.5 percent it rises to about 93 percent. These are illustrations of the compounding rule, not measurements from any particular plant, and real coupling yields vary with the sequence, the resin loading and the activation chemistry. The point is that a small per-step shortfall becomes a large fraction of failure sequences over a long chain, and every one of those failure sequences has to be removed by chromatography or it ends up in the vial.

Microwave heating is one of the ways manufacturers push coupling and deprotection closer to completion, particularly for sequences that aggregate on the resin. Pedersen and colleagues reviewed the approach (Chem Soc Rev 2012;41:1826-1844) and reported that it often shortens synthesis times and raises crude purity for sheet-forming and sterically hindered sequences, while noting that conditions have to be adjusted for cysteine, histidine and aspartic acid residues. Faster synthesis is not automatically cleaner synthesis.

The Impurities SPPS Leaves Behind

Deletion sequences arise when a coupling fails at one position and the chain continues without that residue. They differ from the target by a single amino acid, so they often elute close to the main peak and can be difficult to resolve by HPLC alone. Truncated sequences result when a chain terminates early, and because they are shorter and more different in hydrophobicity they are usually easier to separate. Coin, Beyermann and Bienert (Nat Protoc 2007;2:3247-3256) describe how so-called difficult sequences, where the growing chain aggregates on the resin and blocks reagent access, generate exactly these failure products at specific positions, and how the synthesis has to be adapted to get past them. The analytical side of this is covered in the guide to peptide impurity profiling.

Fmoc chemistry adds side reactions of its own. Aspartimide formation, in which an aspartic acid side chain cyclises onto the backbone under repeated piperidine treatment, produces a mixture of alpha-linked, beta-linked and partially racemised products at the same mass as the parent peptide, which is why it cannot be caught by a molecular weight check. Mergler and colleagues characterised the problem across a series of papers beginning in 2003 (J Pept Sci 2003;9:36-46). Diketopiperazine formation at the dipeptide stage, methionine oxidation to the sulfoxide, and racemisation at individual residues are the other recurring by-products. The site treats methionine oxidation in TB-500 and chiral purity limits in their own articles. The quality of the protected amino acids fed into the synthesis matters as much as the cycle itself, a topic covered in the article on Fmoc amino acid starting materials.

Finally, the cleavage and purification steps leave a signature. Trifluoroacetic acid is used to release the peptide from the resin and again as the ion-pairing agent in reverse-phase purification, so a lyophilised research peptide is normally supplied as a trifluoroacetate salt. The counterion is invisible at the ultraviolet wavelengths used for the purity assay, which is why it needs a separate test, as explained in the articles on residual TFA and counterion content and charged aerosol detection.

Liquid-Phase Peptide Synthesis (LPPS)

LPPS, also called solution-phase synthesis, is the older approach and conducts every reaction in solution without a solid support. Each intermediate can be isolated and characterised, which gives tighter control over the growing chain, but each intermediate also has to be worked up and purified before the next coupling, so the labour scales badly with chain length. The method remains attractive for short peptides made in kilogram quantities, where the resin, the large solvent volumes consumed by washing, and the loading limits of a solid support become the dominant costs. Isidro-Llobet and colleagues (J Org Chem 2019;84:4615-4628) set out the sustainability and cost pressures across both routes from the perspective of pharmaceutical process chemists, including the solvent burden that makes SPPS hard to scale and the reasons hybrid strategies are being pursued.

The impurity profile of a solution-phase peptide is different. Because intermediates are purified as they go, cumulative deletion sequences are less of a problem, but the route depends on side-chain protecting groups that must all be removed at the end, and incomplete deprotection or protecting-group migration are the characteristic failures. Racemisation at the activated C-terminal residue during fragment coupling is a well-known risk whenever two protected fragments are joined in solution.

Hybrid and Convergent Synthesis Approaches

Modern manufacturing increasingly combines the two. In fragment condensation, short protected fragments are made by SPPS, purified individually, and then joined in solution, which resets the cumulative error at each junction. For longer chains, native chemical ligation, introduced by Dawson, Muir, Clark-Lewis and Kent (Science 1994;266:776-779), joins unprotected peptide segments through a thioester and an N-terminal cysteine to give a native amide bond, and Kent’s later review (Chem Soc Rev 2009;38:338-351) describes how it made chemical synthesis of whole proteins practical. For the sub-50-residue compounds that make up most research peptide catalogues, linear Fmoc SPPS followed by preparative reverse-phase HPLC remains the norm. The route tells a researcher what to look for, not what was found.

How Synthesis Method Affects COA Interpretation

HPLC Purity Assessment

The purity figure on a Certificate of Analysis is a relative area: the target peak as a percentage of all ultraviolet-absorbing peaks at the detection wavelength, typically 214 or 220 nm where the peptide bond absorbs. Because deletion and aspartimide products absorb at the same wavelength and elute close to the parent, the reported number depends on the column, gradient and wavelength the laboratory used, which is why the method conditions belong on the certificate and why two laboratories can disagree about the same vial. Under the European Pharmacopoeia general monograph on substances for pharmaceutical use, peptide-related impurities are reported above 0.1 percent, identified above 0.5 percent and qualified above 1.0 percent, thresholds examined in the article on peptide impurity thresholds. A 98 percent purity value therefore says nothing about whether the remaining 2 percent is one identified species or a dozen unidentified ones.

Mass Spectrometry Confirmation

HPLC measures how much of the sample is the main peak. Mass spectrometry confirms what the main peak is. Electrospray ionisation gives the intact molecular mass, and a single deletion shifts that mass by the weight of the missing residue, so an identity check distinguishes the target from a deletion product even when the two co-elute. It does not distinguish an aspartimide or a racemised residue, both of which have the same mass as the parent, and it cannot see a contaminating peptide that was never looked for. Janvier and colleagues (Talanta 2018;188:795-807) analysed 27 peptide preparations bought from illegal internet vendors and found GHRP-2 samples reporting 99.4 to 99.9 percent purity by LC-UV that carried undeclared AOD-9604 visible only by mass spectrometry, along with material labelled as TB-500 that was actually full-length thymosin beta-4. Purity and identity are separate questions answered by separate instruments, a distinction covered in depth in the article on mass spectrometry in peptide purity research.

Why Independent Third-Party Testing Matters

A manufacturer’s in-house certificate is generated with the manufacturer’s own column, gradient and integration settings, and the manufacturer has a commercial interest in the result. An independent laboratory with no stake in the outcome removes that bias and, if it publishes its method conditions, lets a researcher judge whether closely eluting impurities could have been resolved at all. Maple Research Labs publishes independent third-party reports for tested batches on its Certificates of Analysis page, where each listed compound shows the report number, lot, measured HPLC-UV purity and test date, and where the compounds still awaiting a certificate are listed as such. Researchers can read the published reports for products such as BPC-157, GHK-Cu and TB-500 before ordering, and browse the full Maple Research Labs peptide catalog.

Practical Implications for Peptide Researchers in Canada

The synthesis route is rarely stated, but a well-documented certificate lets a researcher infer a great deal. The full chromatogram, not just the purity number, shows whether shoulder peaks sit on the main peak, which is the fingerprint of deletion and aspartimide products from a difficult sequence. The mass spectrum should match the theoretical mass of the intended sequence, and a systematic offset points to incomplete deprotection or a modification. The certificate should carry the lot number of the material being sold, because every synthesis campaign has its own failure pattern and a report from a different lot describes a different impurity profile. For a walkthrough of the document itself, see the guide to reading peptide COAs, the explanation of HPLC purity testing, and the comparison of third-party vs. in-house testing methods.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

References: Merrifield RB. J Am Chem Soc 1963;85:2149-2154. Carpino LA, Han GY. J Org Chem 1972;37:3404-3409. Behrendt R, White P, Offer J. J Pept Sci 2016;22:4-27. Coin I, Beyermann M, Bienert M. Nat Protoc 2007;2:3247-3256. Mergler M, Dick F, Sax B, Weiler P, Vorherr T. J Pept Sci 2003;9:36-46. Pedersen SL, Tofteng AP, Malik L, Jensen KJ. Chem Soc Rev 2012;41:1826-1844. Isidro-Llobet A et al. J Org Chem 2019;84:4615-4628. Dawson PE, Muir TW, Clark-Lewis I, Kent SB. Science 1994;266:776-779. Kent SB. Chem Soc Rev 2009;38:338-351. Janvier S et al. Talanta 2018;188:795-807. For peer-reviewed research on this topic, visit PubMed.